The Rotavirus Vaccine Market is estimated at US$2.9 billion in 2026 and is projected to grow at a CAGR of 9.9% to reach US$6.2 billion by 2034.
Core applications include routine infant immunization, public health vaccination programs, pediatric disease prevention, hospital vaccination support, and global health initiatives. At the same time, suppliers must respond to cold chain dependence, procurement budget limits, vaccine hesitancy in some settings, and supply coordination across immunization programs.
This product will be delivered within 1-3 business days.
Market Overview
The Rotavirus Vaccine Market covers oral and related vaccine products designed to prevent rotavirus infection through immunization programs, pediatric care channels, and public health campaigns. Its value chain includes vaccine developers, biologics manufacturers, cold chain providers, public procurement agencies, pediatric care networks, and distributors.Core applications include routine infant immunization, public health vaccination programs, pediatric disease prevention, hospital vaccination support, and global health initiatives. At the same time, suppliers must respond to cold chain dependence, procurement budget limits, vaccine hesitancy in some settings, and supply coordination across immunization programs.
Key Companies Analysed
- GlaxoSmithKline
- Merck & Co.
- Bharat Biotech
- Serum Institute of India
- Sanofi
- Biological E
- Pfizer
- Valneva
- Sinovac
- Bio Farma
- SK bioscience
- Takeda
- Panacea Biotec
- Hilleman Laboratories
- Incepta Vaccine
- Walvax Biotechnology
- CanSino Biologics
- Vabiotech
- Zydus Lifesciences
- Mitsubishi Tanabe Pharma
Geographic Coverage
- North America - Market data and outlook to 2034
- United States
- Canada
- Mexico
- Europe - Market data and outlook to 2034
- Germany
- United Kingdom
- France
- Italy
- Spain
- Netherlands
- Switzerland
- Poland
- Sweden
- Russia
- Asia-Pacific - Market data and outlook to 2034
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Malaysia
- Vietnam
- Middle East and Africa - Market data and outlook to 2034
- Saudi Arabia
- South Africa
- Iran
- UAE
- Egypt
- South and Central America - Market data and outlook to 2034
- Brazil
- Argentina
- Chile
- Peru
Report Delivery and Support
- Updated PDF report and an MS Excel workbook containing market tables and figures.
- 7-day post-sale analyst support for clarifications and in-scope supplementary data.
- Complimentary report update covering the latest available data and relevant market developments.
This product will be delivered within 1-3 business days.
Table of Contents
1. Contents and Report Guide
2. Global Rotavirus Vaccine Market Overview
3. Rotavirus Vaccine Market Dynamics
4. Rotavirus Vaccine Market Strategic Analysis
5. Global Rotavirus Vaccine Market Size, Share and Forecast, 2025-2034
6. North America Rotavirus Vaccine Market Outlook to 2034
7. Europe Rotavirus Vaccine Market Outlook to 2034
8. Asia-Pacific Rotavirus Vaccine Market Outlook to 2034
9. Middle East and Africa Rotavirus Vaccine Market Outlook to 2034
10. South and Central America Rotavirus Vaccine Market Outlook to 2034
11. Rotavirus Vaccine Market Competitive Landscape
12. Appendix
Companies Mentioned
- GlaxoSmithKline
- Merck & Co.
- Bharat Biotech
- Serum Institute of India
- Sanofi
- Biological E
- Pfizer
- Valneva
- Sinovac
- Bio Farma
- SK bioscience
- Takeda
- Panacea Biotec
- Hilleman Laboratories
- Incepta Vaccine
- Walvax Biotechnology
- CanSino Biologics
- Vabiotech
- Zydus Lifesciences
- Mitsubishi Tanabe Pharma
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | October 2026 |
| Forecast Period | 2026 - 2034 |
| Estimated Market Value ( USD | $ 2.9 Billion |
| Forecasted Market Value ( USD | $ 6.2 Billion |
| Compound Annual Growth Rate | 9.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
